Comparative Pharmacology
Head-to-head clinical analysis: ACCURETIC versus PRINIVIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCURETIC versus PRINIVIL.
ACCURETIC vs PRINIVIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACCURETIC is a combination of quinapril, an angiotensin-converting enzyme (ACE) inhibitor, and hydrochlorothiazide, a thiazide diuretic. Quinapril inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing diuresis and lowering blood pressure.
Lisinopril is an angiotensin-converting enzyme inhibitor that decreases angiotensin II production, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
One tablet orally once daily. Initial dose is 20 mg quinapril/12.5 mg hydrochlorothiazide, titrated to maximum 20 mg quinapril/25 mg hydrochlorothiazide.
Initial dose 10 mg orally once daily; titrate to target dose of 20-40 mg daily based on blood pressure response.
None Documented
None Documented
Quinapril: 0.8 hours; Quinaprilat (active): 2 hours in young healthy adults, prolonged to 3-4 hours in elderly or renal impairment.
Terminal elimination half-life is approximately 12 hours, with accumulation noted in renal impairment; effective half-life at steady state extends to 30-50 hours in patients with creatinine clearance <30 mL/min.
Renal: approximately 90% (60% unchanged, 30% as metabolites). Fecal/biliary: <10%.
Renal excretion accounts for approximately 60% of total clearance, primarily as unchanged lisinopril; fecal excretion accounts for negligible amounts.
Category C
Category C
ACE Inhibitor/Diuretic Combination
ACE Inhibitor